Azentyx Life Pvt. Ltd. has commissioned a new production line at its Baddi facility, expanding annual tablet manufacturing capacity to meet rising demand from domestic distributors and export partners. The addition reflects the company’s continued investment in WHO-GMP certified infrastructure and its commitment to reliable, high-volume supply.
The new line has been integrated into the existing facility without disruption to ongoing production schedules, and has already completed validation runs ahead of full commercial output. This expansion is part of a broader capacity roadmap the company has been executing over the past two years.
Key highlights
- New tablet line commissioned at the Baddi, Solan (HP) facility.
- Annual capacity increased to support both domestic and export order volumes.
- Line validated under existing WHO-GMP quality protocols.
- No disruption to existing client production schedules during commissioning.
Azentyx Life continues to invest in scalable, compliant manufacturing infrastructure as part of its long-term growth strategy. Further updates on capacity and facility developments will be shared through this News & Circulars section as they are finalized.